Real-World Long-Term Ivacaftor for Cystic Fibrosis in France: Clinical Effectiveness and Healthcare Resource Utilization
Dominique Hubert,Christophe Marguet,Jacques Benichou,Cynthia DeSouza,Catherine Payen-Champenois,Nils Kinnman,Keval Chandarana,Anne Munck,Isabelle Fajac,Sophie Ramel,Philippe Vigneron,Veronique Storni,Natacha Remus,Laurence Bassinet Isabelle Durieu,Muriel Laurans,Cinthia Rames Françoise Troussier,Marie-Laure Dalphin Frédéric Huet,Isabelle Pin,Boubou Camara Annabelle Payet,Jeanne Languepin,Isabelle Danner-Boucher,Marc Albertini Julie Mankikian,Nathalie Wizla,Laure Cosson,Eric Deneuville Marie Mittaine,Philippe Reix,Nadine Dufeu,Valérie David,Thierry Langin Stéphanie Bui,Raphael Chiron,Dominique Grenet,Frédérique Chedevergne,Chantal Belleguic,Laurent Mely,,
DOI: https://doi.org/10.1007/s41030-021-00158-5
2021-06-08
Pulmonary Therapy
Abstract:IntroductionIvacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator that has demonstrated clinical benefits in phase 3 trials. We report results from a real-world study (BRIO) to assess the effectiveness of ivacaftor in people with cystic fibrosis (pwCF) in France.MethodsBRIO was an observational study conducted at 35 centers in France. Both pwCF initiating ivacaftor treatment and those already taking ivacaftor were included and prospectively followed for 24 months. The primary objective was to evaluate the effect of ivacaftor on percent predicted forced expiratory volume in 1 s (ppFEV1); secondary objectives were evaluating the effect of ivacaftor on clinical effectiveness, healthcare resource utilization (HCRU), and safety.ResultsA total of 129 pwCF were enrolled; 58.9% were aged < 18 years; 64.3% had a G551D-CFTR allele. Mean age at ivacaftor initiation was 19.1 years (range, 2–64 years); ppFEV1 increased by a least squares mean of 8.49 percentage points in the first 6 months and was sustained through 36 months of ivacaftor use. Growth metrics increased during the first 12 months post-ivacaftor and remained stable. The rate of pulmonary exacerbations (PEx) decreased during the 12 months post-ivacaftor compared with the 12 months pre-ivacaftor; estimated rate ratios (95% CI) were 0.57 (0.43–0.75) for PEx events and 0.25 (0.13–0.48) for PEx requiring hospitalization. No new safety concerns were identified; no deaths occurred.ConclusionsThe results from this real-world study of ivacaftor usage in France were consistent with prior clinical trial outcomes, confirming the clinical effectiveness of ivacaftor, as well as an associated reduction in HCRU.